葛兰素史克(GSK)今日盘中股价大幅上涨5.31%，引发市场广泛关注。
消息面上，公司在盘前公布的2026年第二季度业绩报告显示，调整后每股收益为50.5便士，明显高于市场预估的46.8便士，盈利表现超出预期。此外，公司宣布计划到2029年全面实现每年19亿英镑的成本节约，并宣布未来三年内在英国投资4亿英镑，于剑桥生物医学园区建立新旗舰研发中心，以加速肿瘤学、疫苗等核心领域的研发管线推进。公司首席执行官还表示，现有营收与收益流规模足以抵消艾滋病药物专利失效带来的损失，进一步增强了投资者信心。
强劲的业绩表现、明确的成本优化目标以及研发领域的战略投资，共同推动了葛兰素史克今日盘中的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.